Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond (Leukemia, (2018), 32, 2, (252-262), 10.1038/leu.2017.329)

C. S. Chim, S. K. Kumar, R. Z. Orlowski, G. Cook, P. G. Richardson, M. A. Gertz, S. Giralt, M. V. Mateos, X. Leleu, K. C. Anderson

Research output: Contribution to journalComment/debatepeer-review

Abstract

Following the publication of this article the authors noted that the MRD data under the Table 1 column “Remark” of Aspire should go to that of Pollux. The authors wish to apologize for any inconvenience caused. The corrected table is attached to this correction.

Original languageEnglish (US)
Pages (from-to)1058-1059
Number of pages2
JournalLeukemia
Volume33
Issue number4
DOIs
StatePublished - Apr 1 2019

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond (Leukemia, (2018), 32, 2, (252-262), 10.1038/leu.2017.329)'. Together they form a unique fingerprint.

Cite this